Zura Bio Limited is a clinical-stage immunology company dedicated to developing novel medicines for patients with severe autoimmune and inflammatory diseases. The company's business model centers on in-licensing and advancing clinical-stage product candidates that target key mechanisms of immune system imbalance. Zura Bio's lead asset is tibulizumab (ZB-106), a first-in-class bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule. Tibulizumab is being evaluated in Phase 2 clinical studies for the treatment of systemic sclerosis (SSc) and hidradenitis suppurativa (HS). In addition to tibulizumab, the company's pipeline includes two other assets that have completed Phase 1 studies: torudokimab (ZB-880), a fully human monoclonal antibody targeting interleukin-33 (IL-33), and crebankitug (ZB-168), a fully human monoclonal antibody targeting interleukin-7 receptor alpha (IL-7Rα). As a pre-revenue biotechnology company, Zura Bio relies on capital raises to fund its research and development activities. The company operates primarily in the United States and is headquartered in Henderson, Nevada, while being legally domiciled in the Cayman Islands. Zura Bio became a publicly traded entity in March 2023 following a business combination with the special purpose acquisition company (SPAC) JATT Acquisition Corp.
